Asymptomatic Atherosclerosis
Pathophysiology, Detection and Treatment
Samenvatting
Despite recent advances in the diagnosis and treatment of symptomatic atherosclerosis, available traditional screening methods for early detection and treatment of asymptomatic coronary artery disease are grossly insufficient and fail to identify the majority of victims prior to the onset of a life-threatening event. In Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment, Dr. Morteza Naghavi and leading authorities from the Society for Heart Attack Prevention and Eradication (SHAPE) present a new paradigm for the screening and primary prevention of asymptomatic atherosclerosis. The text focuses on accurate, yet underutilized, measures of subclinical atherosclerosis, notably coronary artery calcium scanning and carotid intima-media thickness measurement. The authors introduce a comprehensive approach to identifying the vulnerable patients (asymptomatic individuals at risk of a near future adverse event). Additional chapters discuss future directions towards containing the epidemic of atherosclerotic cardiovascular disease using innovative solutions such as preemptive interventional therapies (bioabsorbable stents) for stabilization of vulnerable atherosclerotic plaques, mass unconditional Polypill therapy for population-based risk reduction, and ultimately vaccination strategies to prevent the development of atherosclerosis. Up-to-date and authoritative, Asymptomatic Atherosclerosis: Pathophysiology, Detection, and Treatment is a must-have for any cardiologist or primary care physician who wishes to practice modern preventive cardiology and manage the increasing number of asymptomatic atherosclerotic patients. Outlines more accurate measures of risk (coronary artery calcium and carotid intima-media thickness) than traditional risk factors (total cholesterol, LDL cholesterol, HDL cholesterol) Presents new multipronged strategies to aid in the early detection and treatment of high risk asymptomatic patients
Specificaties
Inhoudsopgave
<P></P>
<P>15. Exercise stress testing in asymptomatic individuals and its relation to <BR>subclinical atherosclerotic cardiovascular disease</P>
<P>16. The Ankle Brachial Index</P>
<P>17. Arterial Elasticity/Stiffness</P>
<P>18. Assessment of Endothelial Function in Clinical Practice <BR></P>
<P>19. Digital (Fingertip) Thermal Monitoring of Vascular Function: A Novel Non-</P>
<P>invasive Non-imaging Test to Improve Traditional Cardiovascular Risk </P>
<P>Assessment and Monitoring of Response to Treatments <BR></P>
<P>20. Assessment of Macro & Micro Vascular Function and Reactivity <BR></P>
<P>Non Invasive Structural Imaging of Subclinical ACVD</P>
<P></P>
<P>21. Computed Tomographic Angiography </P>
<P>22. Carotid Intima-Media Thickness </P>
<P>23. Carotid intima-media thickness: clinical implementation in individual </P>
<P>cardiovascular risk assessment </P>
<P></P>
<P>24. Non-Invasive Coronary CT Angiography</P>
<P>25. Non-Invasive CT v.s. MRI for Characterization of Atherosclerosis Plaque</P>
<P>26. Non-Invasive Magnetic Resonance Imaging of Aorta and Coronary Arteries</P>
<P>27. The Role of MRI in Examining Subclinical Carotid Plaque</P>
<P>Non Invasive Functional Imaging of Subclinical ACVD</P>
<P>28. Ultrasound Imaging of Brachial Artery Reactivity (FMD)</P>
<P>29. Silent and Stress-Induced Myocardial Ischemia</P>
<P>30. Targeted MRI of Molecular Components in Atherosclerotic Plaque </P>
<P>31. Non Invasive imaging of vulnerable myocardium- MRI and CT based</P>
<P>Invasive Assessment of ACVD</P>
<P>32. Angiographic Detection of Complex and Vulnerable Atherosclerotic Plaques</P>
<P>33. Intravascular Methods for Characterizing Potentially High Risk Coronary </P>
<P>Plaques. <BR>34. Detecting Vulnerable Plaque Using Invasive Methods</P>
<P>35. Assessment of Plaque Burden and Composition using Intravascular <BR>Ultrasound</P>
<P>36. Vasa Vasorum Imaging: A New Window to the Detection of Vulnerable <BR>Atherosclerotic Plaques</P>
<P>37. The First SHAPE Guideline; </P>
<P>38. Cost-Effectiveness of Screening for Atherosclerosis vs. Screening for Risk <BR>Factors of Atherosclerosis</P>
<P>39. Monitoring of Subclinical Atherosclerotic Disease</P>
<P>40. Implications of SHAPE Guideline for Improving Patient Compliance</P>
<P>41. The Cost-Conscious SHAPE Guideline – Why Primary Care Physicians <BR>Should Embrace It</P>
<P>42. Should we treat based on SHAPE guidelines??</P>
<P>43. Duty-Bound: Philosophical Foundations of Clinical Strategies for Prevention <BR>of Cardiovascular Events</P>
<P>44. Dynamic Changes in Risk as the Basis for Therapeutic Triage</P>
<P>Treatment of Subclinical ACVD and Vulnerable Patients </P>
<P>Systemic Therapies</P>
<P></P>
<P>45. LDL Targeted Therapies</P>
<P>46. Antioxidants as targeted therapy: a special protective role for pomegranate <BR>and paraoxonases (PONs)</P>
<P>47. Multi-Constituent Cardiovascular Pills (MCCP) – Challenges and Promises of Population Based Prophylactic Drug Therapy for Prevention of Heart Attack</P>
<P>48. Vaccine for Atherosclerosis: An Emerging New Paradigm </P>
<P>Focal Therapies for Vulnerable Arteries and Plaques</P>
<P>49. Drug Eluting Stents: A Potential Preemptive Treatment Choice for <BR>Vulnerable Coronary Plaques</P>
<P></P>
<P>50. Intrapericardial Approach for Pan Coronary Stabilization of the Vulnerable <BR>Arteries and Myocardium</P>
<P>Educations, Life Style Modifications and Non-pharmacologic Therapies for the <BR>Atherosclerosis Susceptible and ACVD Vulnerable Population<BR></P>
<P>51. Dietary Management for Coronary Atherosclerosis Prevention & <BR>Treatment</P>
<P>52. Management of Preconditioning Physical Activity in a Vulnerable Patient; Getting in SHAPE</P>
<P><STRONG>53.</STRONG> Acute Prevention of the Heart Attack: the Identification of Prodromal <BR>Symptom Recognition as the "Rosetta Stone" in Solving the Heart Attack <BR>Problem</P>
<P></P><STRONG></STRONG>